Adverse events of inactivated COVID-19 vaccine in HIV-infected adults

Table 1 Baseline data for all participants

Characteristic	Patients with HIV/AIDS (n = 259)	Dose 1(N = 259)				Dose 2 (N = 236)
Characteristic	Patients with HIV/AIDS (n = 259)	With adverse events	Without adverse events	χ²	P	With adverse events	Without adverse events	χ²	P
Age group
≤ 35	116	30	86			11	89
> 35	143	29	114	1.14	0.29	13	123	0.13	0.72
Gender
Male	240	55	185			21	197
Female	19	4	15	0.04	0.85	3	15	0.90	0.34
Marital status
Singe	169	42	127			17	136
Married	36	6	30			3	31
Other	54	11	43	1.36	0.51	4	45	0.43	0.81
Occupation
Unemployment	37	7	30			2	33
Employment	222	52	170	0.37	0.55	22	179	0.89	0.35
Education level
High school or lower	76	17	59			6	62
Higher than high school	183	42	141	0.01	0.92	18	150	0.19	0.66
Comorbidities
Yes	38	6	32			5	30
No	221	53	168	1.24	0.27	19	182	0.76	0.38
NNRTIs (NVP/EFV)
Yes	216	47	169			17	180
No	43	12	31	0.77	0.38	7	32	–	0.09
INSTIs (EVG/DTG)
Yes	26	5	21			1	22
No	233	54	179	0.21	0.65	23	190	–	0.48
PIs (LPV/r)
Yes	14	5	9			5	8
No	245	54	191	0.74	0.39	19	204	9.00	0.003
CD4
≤ 350	49	8	41			5	38
> 350	210	51	159	1.43	0.23	19	174	0.12	0.73
HIV viral load
Undetectable	208	49	159			19	172
Detectable	51	10	41	0.36	0.55	5	40	–	0.79

NNRTIs nonnucleoside reverse transcriptase inhibitors; INSTIs integrase inhibitors; PIs protein inhibitors; NVP nevirapine; EFV efavirenz; EVG elvitegravir; DTG dolutegravir; LPV/r lopinavir/ritonavir; – no statistics are computed because Fisher exact method was used

ISSN: 1742-6405